<DOC>
	<DOCNO>NCT00005050</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine eniluracil , fluorouracil , oxaliplatin treat patient advanced colorectal cancer treat previously .</brief_summary>
	<brief_title>Eniluracil , Fluorouracil , Oxaliplatin Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , dose limit toxicity , recommend phase II dose eniluracil , fluorouracil , oxaliplatin patient previously treat advanced colorectal cancer . II . Determine response rate patient treat regimen . OUTLINE : This dose escalation study eniluracil fluorouracil . Patients receive oral eniluracil oral fluorouracil twice daily day 1-21 . Patients receive oxaliplatin IV 2 hour day 1 15 . Treatment continue every 4 week absence disease progression unacceptable toxicity . Patients complete response treat 2 course therapy stop . Cohorts 3-6 patient receive escalate dos eniluracil fluorouracil maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . The recommended phase II dose ( RPTD ) define 1 dose level MTD . Patients follow 1 month . PROJECTED ACCRUAL : A total 3-30 patient accrued phase I study , additional 27-40 patient accrue phase II study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Eniluracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced colorectal cancer No 2 prior chemotherapy regimen include fluorouracil and/or irinotecan ( relapse within 6 month adjuvant therapy consider 1 prior regimen ) Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN No significant hepatic dysfunction Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : No significant cardiovascular dysfunction Neurologic : No dementia alter mental status would preclude informed consent No grade 3 motor sensory neuropathy No significant neurologic dysfunction Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No malabsorption syndrome disease significantly affect gastrointestinal function would preclude absorption eniluracil fluorouracil No active infection require systemic therapy within 1 week study No known platinum allergy No significant endocrine dysfunction PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Recovered prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy Surgery : No major resection stomach proximal small bowel would preclude absorption eniluracil fluorouracil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>